David Krempa
Chief Business Officer · Eton Pharmaceuticals, Inc.
- 2024
- Oct 6, 2026
- 8
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies David Krempa files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Sean Brynjelsen - $9.91M in ETON purchases and sales in the last 12 months
- Opaleye Management Inc. - $6.89M in ETON purchases and sales in the last 12 months
- Paul V. Maier - $5.91M in ETON purchases and sales in the last 12 months
- Jennifer McKie Adams - $1.62M in ETON purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is David Krempa?
David Krempa is a corporate insider, tracked as Chief Business Officer of Eton Pharmaceuticals, Inc. (ETON). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has David Krempa submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has David Krempa been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($5.09M) across all tracked filings.
